Update shared on04 Sep 2025
Fair value Increased 8.72%The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations.
What's in the News
- President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).
- The U.S. House of Representatives has passed an amendment allowing VA doctors to recommend medical cannabis to veterans in states where it is legal, supporting broader access to cannabis products from companies like Cronos Group (Marijuana Herald).
- Cronos Group successfully completed a share repurchase program, buying back approximately 1.87 million shares (0.49% of shares outstanding) for a total of $3.61 million between May 7 and June 30, 2025 (Company Key Development).
- Cronos Group expanded the distribution of its PEACE NATURALS® medical cannabis brand in Switzerland through a partnership with Dascoli Pharma AG, strengthening its footprint in European medical cannabis markets (Company Key Development).
- The strategic agreement with Dascoli will introduce several PEACE NATURALS® cannabis flower strains to Swiss medical patients, aligning with Cronos Group's ongoing international expansion strategy (Company Key Development).
Valuation Changes
Summary of Valuation Changes for Cronos Group
- The Consensus Analyst Price Target has risen from CA$3.63 to CA$3.95.
- The Future P/E for Cronos Group has significantly risen from 26.35x to 39.64x.
- The Consensus Revenue Growth forecasts for Cronos Group remained effectively unchanged, at 6.5% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.